

Table S1. Oligonucleotide primer sequences

Primer	Gene	Experiment	Direction	Sequence
SBP1-5′	<i>sbp1</i>	Cloning	forward	ATATATATCCATGGAACCAAAGAAGAAACCAGCACC
SBP1-3′	<i>sbp1</i>	Cloning	reverse	TCTCTCGGATCCTAAAGCTGCATCAAACCTCAGC
SBP2-5′	<i>sbp2</i>	Cloning	forward	TCTCTCCATGGAAGCAATGAGTCTACGACCAAT
SBP2-3′	<i>sbp2</i>	Cloning	reverse	CTCTGGATCCTTGACCTAATGCTTGGCTGTT
SBP3-5′	<i>sbp3</i>	Cloning	forward	TCTCTCCATGGAAGCGGTCAAACGAACAAAGC
SBP3-3′	<i>sbp3</i>	Cloning	reverse	TCTCTGGATCCTTCAATATTAGTTGGCATAACC
SBP123kanmutup5′	<i>sbp123</i> <i>sbp1</i>	Mutant construction	forward	TATTTGCTTCTCCGATACCCA
SBP123kanmutup3′	<i>sbp123</i> <i>sbp1</i>	Mutant construction	reverse	TAGTTAGTCAGATAATTCCTTGGGTTAATA
SBP123kan5′	<i>sbp123</i> <i>sbp1</i>	Mutant construction	forward	AGGAATTATCTGACTAACTAGGAGGAATAA

SBP123kan3'	<i>sbp123</i> <i>sbp3</i>	Mutant construction	reverse	GTCTTATTCACATTATTCCTCCAGGTACT
SBP123kanmutdn5'	<i>sbp123</i>	Mutant construction	forward	AGGGAATAATGTGAATAAGACTGCCAAAAA
SBP123kanmutdn3'	<i>sbp123</i>	Mutant construction	reverse	AAGCACAAGACAGGACCACA
SBP1kan3'	<i>sbp1</i>	Mutant construction	reverse	TGTGCCAAACCATTATTCCTCCAGGTACT
SBP1kanmutdn5'	<i>sbp1</i>	Mutant construction	forward	GGGAATAATGGTTTGGCACACCTACTTTTG
SBP1kanmutdn3'	<i>sbp1</i>	Mutant construction	reverse	ATTGTTGGTACATTTAGTAT
SBP2kanmutup5'	<i>sbp2</i>	Mutant construction	forward	GTTTTGCTCGTGAAGTCTCAA
SBP2kanmutup3'	<i>sbp2</i>	Mutant	reverse	TAGTTAGTCACTCTTAATATGCTTAATATG

		construction		
SBP2kan5´	<i>sbp2</i>	Mutant construction	forward	ATATTAAGAGTGACTAACTAGGAGGAATAA
SBP2kan3´	<i>sbp2</i>	Mutant construction	reverse	CGGCTTAAAACATTATCCCTCCAGGTACT
SBP2kanmutdn5´	<i>sbp2</i>	Mutant construction	forward	GGGAATAATGTTTTAAGCCGATGGTGTTTG
SBP2kanmutdn3´	<i>sbp2</i>	Mutant construction	reverse	CTTAGCCAATCATTAAAAG
SBP3kanmutup5´	<i>sbp3</i> <i>sbp2</i>	Mutant construction <i>sbp2</i> sequencing	forward	GCGGTAAATTGGCAGAAATTG
SBP3kanmutup3´	<i>sbp3</i>	Mutant construction	reverse	TAGTTAGTCAAATCTACTCCTTGATTTGGTG

SBP3kan5'	<i>sbp3</i>	Mutant construction	forward	GGAGTAGATTTGACTAACTAGGAGGAATAA
SBP3kanmutdn5'	<i>sbp3</i>	Mutant construction	forward	GGGAATAATGTGAATAAGACTGCCAAAAAG
SBP3kanmutdn3'	<i>sbp3</i>	Mutant construction	reverse	CAAAGCACAAGACAGGACCAC
P14-S2-R	<i>sbp2</i>	<i>sbp2</i> sequencing	reverse	CTAAATGTACCAACAATGGCTG

Table S2. Comparison of *sbp2* sequence (804bp/267aa) between *M. catarrhalis* strain O35E and clinical isolates

Clinical source (n)	Total number of isolates	Nucleotide position			
		97	244	615	769
AOM(2), COPD(2), NP(3) ^a	n= 7	G	G	C	G
AOM(6), COPD(8), NP(5) ^b	n=19	A	G	T	G
AOM(1), COPD(0), NP(1)	n= 2	G	A	C	G
AOM(1), COPD(0), NP(1)	n= 2	G	G	C	A
Substitution of amino acid ^c		A33T	A82T	-	A257T

^a *sbp2* sequence of strain O35E is identical.

AOM, acute otitis media; COPD, chronic obstructive pulmonary disease; NP, nasopharynx

^b *sbp2* sequence of strain BBH18 is identical.

^c A, alanine; T, threonine